search
Back to results

Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting

Primary Purpose

PONV

Status
Unknown status
Phase
Phase 2
Locations
Malaysia
Study Type
Interventional
Intervention
Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg
Granisetron 1 Mg/mL Intravenous Solution
Sponsored by
Universiti Sains Malaysia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PONV focused on measuring Caesarean, Morphine, Granisetron

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • American Society of Anaesthesiologists (ASA) I-II category
  • 2 risks factors or more for PONV according to Apfel Score.

Exclusion Criteria:

  • Unfit for spinal anaesthesia.
  • Coagulopathy
  • Uncorrected hypovolemia
  • Indeterminate neurologic disease
  • Infection at site of injection
  • Raised intracranial pressure(ICP)
  • Morbidly obese patients, BMI> 40 kg/m2 according to ICD-10 (International Statistical Classification of Diseases 10)
  • Patients allergic towards morphine.
  • Contraindicated for antiemetics use
  • Granisetron: allergy towards Granisetron, prolonged QT interval
  • Ondansetron: allergy towards ondansetron, prolonged QT interval
  • Dexamethasone: allergy towards Dexamethasone, uncontrolled Diabetes Mellitus (DM).

Sites / Locations

  • Universiti Sains Malaysia, Health CampusRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Granisetron

Granisetron and Dexamethasone

Arm Description

Granisetron 1 mg (1ml) + Normal saline 1ml

Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)

Outcomes

Primary Outcome Measures

Comparing the incidence of post operative nausea and vomiting (PONV)
To compare the incidence of nausea, retching and vomiting at 1 hour, 4 hourly for 12 hours and at 24 hours postoperatively between parturients receiving combination therapy of Granisetron plus Dexamethasone versus that of Granisetron alone

Secondary Outcome Measures

Comparing the requirement of rescue antiemetic between both groups
To compare the requirement of rescue antiemetic between 1 hour, 4 hourly for 12 hours and at 24 hours postoperatively between parturients receiving combination therapy of Granisetron plus Dexamethasone versus that of Granisetron alone

Full Information

First Posted
September 19, 2020
Last Updated
September 29, 2020
Sponsor
Universiti Sains Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT04570592
Brief Title
Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting
Official Title
Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting After Caesarean Section With Intrathecal Morphine: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2020 (Anticipated)
Primary Completion Date
April 1, 2021 (Anticipated)
Study Completion Date
June 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Sains Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Intrathecal morphine (ITM) has proven to be excellent in reducing postoperative pain. However, its use has commonly been associated with the occurrence of postoperative nausea and vomiting (PONV). In recent years, the combination therapy of antiemetics comprising of a serotonin receptor antagonist and corticosteroid has been implemented to diminish the occurrence of PONV. Despite being routinely used, the evidence in the efficacy of this combination in parturients are conflicting and lacking. In this study, we wish to compare the efficacy between the combination therapy of granisetron plus dexamethasone versus granisetron alone on the occurrence of postoperative nausea and vomiting (PONV) in 126 parturients undergoing elective Caesarean delivery supplemented with intrathecal morphine.
Detailed Description
126 parturients aged between 18 and 45 years old who falls within the American Society of Anaesthesiology (ASA) physical status I and II undergoing Caesarean deliveries from the 1st of October 2020 till the 1st of April 2021 will be enrolled. Informed and written consent shall be obtained on recruitment. Subjects will be randomised using a computer-generated randomisation software using block size 3 into 2 groups; group A and group B each consisting of 63 subjects. The order of interventions within each block was random as determined by computer random number generator. This technique was chosen to ensure similar numbers of patients in each group at any point during the study. Both patients and the assessors of PONV which is the Acute Pain Service (APS) team will be blinded. Patients are subjected to fasting 6 hours prior to surgery with clear fluid allowed up to 2 hours before surgery. Intravenous (IV) metaclopromide 10mg, IV ranitidine 50mg and mist sodium citrate 30 mls will be administered as part of the acid aspiration prophylaxis. Standard monitoring with continuous noninvasive blood pressure monitoring (NIBP), electrocardiogram (ECG), respiratory rate and pulse oximetry (SpO2) will be implemented throughout anaesthesia. Ringer's lactate solution 10ml/kg will be infused for coloading to mitigate hypotension post spinal anaesthesia. Spinal anaesthesia will be administered in the upright position, implementing a height-based dose for heavy bupivacaine 0.5% administration. Based on the subject's height, those who are less than 150cm, 151-154cm and those who are more than 155cm will receive 1.5mls, 1.7mls and 1.9mls heavy bupivacaine 0.5% (AstraZeneca) respectively. Fentanyl 15-20 mcg and morphine 0.1 mg are added to supplement the spinal anaesthesia. On the completion of spinal anaesthesia, 4 mg of dexamethasone will be administered to parturients in group A while group B received 1ml of normal saline injected intravenously. 1mg of IV granisetron will be administered to both groups of subjects after cord clamping. These drugs will be given by the anaesthetist administering the spinal anaethesia. The anaesthetist in charge is not blinded as this is of paramount importance in ensuring patients safety should any complication arises during the delivery of anaesthesia. Post surgery, subjects will be monitored in the recovery area for an hour. To supplement ITM as the postoperative analgesia, tablet paracetamol 1g qid and voltaren 50mg tds will be provided to patients postoperatively. The use of opioid is avoided during the first 24 hours of intrathecal morphine administration. Patients will be monitored for complications of ITM for 24 hours and assessments will be carried out by the APS team which include an anaesthetic medical officer and 2 staff nurses. Assessments are made at 1 hour post surgery, 4 hourly for 12 hours post surgery up to 24 hours after surgery. Episodes of nausea, retching and vomiting will be elicited by direct questioning and recorded at each assessors' visit. Nausea is described as an unpleasant sensation related to the urge to vomit. Retching is defined as an involuntary effort to vomit but without the expulsion of the gastric contents, while vomiting is the when expulsion of gastric contents occur. The requirement of rescue antiemetics at each time interval will also be documented. Rescue antiemetic is given when a patient developed one or more episodes of vomiting. IV ondansetron 4 mg is given to group A while either IV dexamethasone 4mg or iv ondansetron is given to group B. Subsequent requirement of antiemetics will be decided based on the anaesthetist discretion. Sample size is calculated based the assumption that the combination of a serotonin receptor antagonist with a corticosteroid would be superior than its monotherapy and thus, the addition of dexamethasone to granisetron would reduce the incidence of PONV from 20% to 3.3%. From the calculation using PS software, the sample required for each group is 57, and with the additional 10% for dropout rate, this study required 63 patients in each group, giving a total of 126 patients. Data analysis will be performed using SPSS version 27 for MAC. The incidences of nausea, retching, vomiting and the use of rescue antiemetic will be analysed using Chi-Square test. Data is presented as percentage and a p-value of <0.05 is considered statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PONV
Keywords
Caesarean, Morphine, Granisetron

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
126 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Granisetron
Arm Type
Placebo Comparator
Arm Description
Granisetron 1 mg (1ml) + Normal saline 1ml
Arm Title
Granisetron and Dexamethasone
Arm Type
Experimental
Arm Description
Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)
Intervention Type
Drug
Intervention Name(s)
Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg
Other Intervention Name(s)
Treatment group
Intervention Description
Comparing PONV incidences in both arms
Intervention Type
Drug
Intervention Name(s)
Granisetron 1 Mg/mL Intravenous Solution
Intervention Description
Comparing PONV incidences in both arms
Primary Outcome Measure Information:
Title
Comparing the incidence of post operative nausea and vomiting (PONV)
Description
To compare the incidence of nausea, retching and vomiting at 1 hour, 4 hourly for 12 hours and at 24 hours postoperatively between parturients receiving combination therapy of Granisetron plus Dexamethasone versus that of Granisetron alone
Time Frame
From 1 to 24 hour post operatively
Secondary Outcome Measure Information:
Title
Comparing the requirement of rescue antiemetic between both groups
Description
To compare the requirement of rescue antiemetic between 1 hour, 4 hourly for 12 hours and at 24 hours postoperatively between parturients receiving combination therapy of Granisetron plus Dexamethasone versus that of Granisetron alone
Time Frame
From 1 to 24 hour post operatively

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Parturients
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: American Society of Anaesthesiologists (ASA) I-II category 2 risks factors or more for PONV according to Apfel Score. Exclusion Criteria: Unfit for spinal anaesthesia. Coagulopathy Uncorrected hypovolemia Indeterminate neurologic disease Infection at site of injection Raised intracranial pressure(ICP) Morbidly obese patients, BMI> 40 kg/m2 according to ICD-10 (International Statistical Classification of Diseases 10) Patients allergic towards morphine. Contraindicated for antiemetics use Granisetron: allergy towards Granisetron, prolonged QT interval Ondansetron: allergy towards ondansetron, prolonged QT interval Dexamethasone: allergy towards Dexamethasone, uncontrolled Diabetes Mellitus (DM).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Farah Nasuha Mohd Daut
Organizational Affiliation
Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universiti Sains Malaysia, Health Campus
City
Kubang Kerian
State/Province
Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Associate Professor W Mohd Nazarudin W Hassan
Phone
09-7673000
Ext
6105
Email
nazarudin@usm.my

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD will be considered for sharing if the data is to be used for related studies.
Citations:
PubMed Identifier
10072014
Citation
Gwirtz KH, Young JV, Byers RS, Alley C, Levin K, Walker SG, Stoelting RK. The safety and efficacy of intrathecal opioid analgesia for acute postoperative pain: seven years' experience with 5969 surgical patients at Indiana University Hospital. Anesth Analg. 1999 Mar;88(3):599-604. doi: 10.1097/00000539-199903000-00026.
Results Reference
background
PubMed Identifier
15830768
Citation
Sfeir S, Mansour N. Post operative analgesia with intrathecal morphine. Middle East J Anaesthesiol. 2005 Feb;18(1):133-9.
Results Reference
background
PubMed Identifier
10598635
Citation
Dahl JB, Jeppesen IS, Jorgensen H, Wetterslev J, Moiniche S. Intraoperative and postoperative analgesic efficacy and adverse effects of intrathecal opioids in patients undergoing cesarean section with spinal anesthesia: a qualitative and quantitative systematic review of randomized controlled trials. Anesthesiology. 1999 Dec;91(6):1919-27. doi: 10.1097/00000542-199912000-00045. No abstract available.
Results Reference
background
PubMed Identifier
15190136
Citation
Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004 Jun 10;350(24):2441-51. doi: 10.1056/NEJMoa032196.
Results Reference
background
PubMed Identifier
3354872
Citation
Abouleish E, Rawal N, Fallon K, Hernandez D. Combined intrathecal morphine and bupivacaine for cesarean section. Anesth Analg. 1988 Apr;67(4):370-4.
Results Reference
result

Learn more about this trial

Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting

We'll reach out to this number within 24 hrs